Bio-Matrix Scientific’s Research Subsidiary, Entest BioMedical, Inc., Files Stem Cell Therapy Patent Application for Treatment o
Posted Aug 21 2009 11:35am
Adipose Stem Cells to Be Used
Bio-Matrix Scientific Group, Inc. (OTCBB: BMSN) announced today its majority owned subsidiary, Entest BioMedical unit (OTCBB: ENTB), has filed a patent application for the use of adipose derived stem cells in the treatment of Chronic Obstructive Pulmonary Disease (COPD). BMSN is excited with the progress achieved by Entest BioMedical, Inc. (OTCBB: ENTB) in identifying diseases it believes will be treatable through Stem Cell Therapy.
Chronic Obstructive Pulmonary Disease is a major health disorder that appears to be treatable through adipose derived stem cell therapy. COPD is a group of lung inflammatory diseases which includes both emphysema and chronic obstructive bronchitis affecting more than 5 million Americans each year. It is the fourth leading cause of death in America, impacting more than 5 million Americans, resulting in more than 120,000 deaths in the USA per year.
Currently, this disease is treated in similar fashion to asthma, utilizing inhalers and /or oxygen therapy. These methods are not solutions to the disease but merely provide the patient with greater level of comfort.
Steven Josephs, PhD. noted, “The approach is intended at the very least to alleviate the chronic inflammation in COPD. This is done by using agents known to coax adult stem cells that are delivered to the diseased lung tissue (blood monocyte cells) to release cytokines (biologically active molecules) which in addition to the anti-inflammatory effects may actually promote the regeneration of functional lung tissue.”
The goal of Entest BioMedical, Inc. is to develop a stem cell therapy that reverses the effects of COPD on the respiratory system. The Company is working with Dr. Feng Lin, its Scientific Director and Steven Josephs, PhD in developing this stem cell treatment.